BMY
the council passes — AVOIDBristol-Myers Squibb Company·Healthcare
Doesn't clear the council's bar right now.
55/100C
Price at last run$57.91as of Jul 8, 2026
healthcareHigh returns on capitalROIC ~13% — it earns well on the money it puts to work.
Strong gross margins64% gross margin.
Generates real cash10.9% free-cash-flow yield — profits you can actually bank.
Catalystnone yet
✕Why not
The honest case against — what most tools hideMain riskshrinking revenue
LeverageCarries meaningful debt (debt/equity 2.0).
ShrinkingRevenue contracting (-0%).
What keeps us out
- Debt rising faster than cash flow.
Patience price & distance
as of Jul 8, 2026 runThe patience price is where value discipline would let the council in — deliberately strict: we'd rather miss ten winners than own one loser.
Catalyst
none yet
A catalyst is a plausible reason the gap could close — never a certainty.